Drug Trial Radar · NCT07218029
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
Last checked: Nov 20, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
815
Planned (sponsor's estimate)
Start
May 12, 2021
Primary completion
Dec 7, 2028
Study completion Dec 7, 2028
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Oct 20, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for more ways to treat PAH. In PAH, the blood vessels in the lungs become thick and narrow, which makes it harder for blood to flow. This causes high blood pressure in the lungs and overworks the heart. PAH can make it hard to breathe and be active. Some standard (usual) treatments for PAH can treat symptoms of PAH but do not stop PAH from getting worse. Sotatercept is a study medicine designed to treat PAH. It is a targeted therapy, which is a treatment that works on certain proteins that play a role in causing PAH. This is a long-term follow-up (LTFU) study. People who took part in certain other studies testing sotatercept for PAH may be able to join this study. The goal of this study is to learn about the long-term safety of sotatercept and if people tolerate it when taken with standard PAH treatment over a longer period of time.
Conditions
- Pulmonary Arterial Hypertension
Interventions
SotaterceptBiological
Sotatercept SC injection every 3 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Experience an Adverse Event (AE)Time frame: Up to approximately 90 months
- Number of Participants Who Discontinue Study Treatment Due to an AETime frame: Up to approximately 86 months
- Number of Participants with Detectable Anti-Drug Antibodies (ADAs)Time frame: Up to approximately 88 months
- Laboratory parameters (Hematology): Concentration of Platelets and HemoglobinTime frame: Up to approximately 88 months
- Laboratory parameters (Chemistry): Concentration of Creatinine, Total Bilirubin, and Alanine Aminotransferase (ALT)Time frame: Up to approximately 86 months
- Change From Baseline in Body WeightTime frame: Baseline and up to approximately 86 months
- Change From Baseline in Blood PressureTime frame: Baseline and up to approximately 86 months
- Change From Baseline in Electrocardiogram (ECG)Time frame: Baseline and up to approximately 86 months
Locations
137 sites in 27 countries. Site status is shown where the registry gives one.
Pulmonary Associates, PA ( Site 1008)
Phoenix, Arizona
Arizona Pulmonary Specialists ( Site 1010)
Scottsdale, Arizona
University of Arizona ( Site 1006)
Tucson, Arizona
University of California San Diego Health ( Site 1002)
La Jolla, California
UC Irvine Health Medical Center ( Site 1086)
Orange, California
UC Davis - Medial Center ( Site 1064)
Sacramento, California
UCSF Helen Diller Medical Center at Parnassus Heights ( Site 1019)
San Francisco, California
Jeffrey S. Sager, MD Medical Corporation ( Site 1060)
Santa Barbara, California
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center ( Site 1028)
Torrance, California
University of Colorado Hospital ( Site 1013)
Aurora, Colorado
George Washington University Medical Faculty Associates ( Site 1025)
Washington D.C., District of Columbia
Mayo Clinic Jacksonville ( Site 1045)
Jacksonville, Florida
AdventHealth Orlando ( Site 1058)
Orlando, Florida
Tampa General Hospital ( Site 1043)
Tampa, Florida
The Emory Clinic ( Site 1030)
Atlanta, Georgia
University of Kansas Medical Center ( Site 1020)
Kansas City, Kansas
Norton Pulmonary Specialists ( Site 1066)
Louisville, Kentucky
Johns Hopkins University ( Site 1036)
Baltimore, Maryland
Tufts Medical Center ( Site 1012)
Boston, Massachusetts
Brigham and Women's Hospital ( Site 1014)
Boston, Massachusetts
University of Minnesota ( Site 1062)
Minneapolis, Minnesota
University Of Nebraska Medical Center ( Site 1053)
Omaha, Nebraska
Weill Cornell Medical Center ( Site 1046)
New York, New York
Duke University Medical Center ( Site 1026)
Durham, North Carolina
The Carl and Edyth Lindner Center for Research and Education at the Christ Hospital ( Site 1001)
Cincinnati, Ohio
University of Cincinnati Medical Center ( Site 1035)
Cincinnati, Ohio
Cleveland Clinic Main ( Site 1065)
Cleveland, Ohio
Ohio State University Wexner Medical Center ( Site 1032)
Columbus, Ohio
Oregon Health & Science University ( Site 1054)
Portland, Oregon
University of Pittsburgh Medical Center - Presbyterian Hosp. ( Site 1059)
Pittsburgh, Pennsylvania
Rhode Island Hospital ( Site 1033)
Providence, Rhode Island
Medical University of South Carolina ( Site 1003)
Charleston, South Carolina
University of Texas Southwestern Medical Center ( Site 1038)
Dallas, Texas
CHI St. Luke's Health Baylor College of Medicine Medical Center ( Site 1044)
Houston, Texas
Houston Methodist Hospital ( Site 1009)
Houston, Texas
Froedtert Hospital & the Medical College of Wisconsin ( Site 1051)
Milwaukee, Wisconsin
Sanatorio Allende ( Site 1908)
Córdoba, Argentina
Hospital Provincial Dr. Jose M. Cullen ( Site 1902)
Santa Fe, Argentina
Instituto de Investigaciones Clinicas Quilmes ( Site 1903)
Quilmes, Buenos Aires, Argentina
Instituto Médico Río Cuarto ( Site 1907)
Río Cuarto, Córdoba Province, Argentina
Showing 40 of 137 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.